Proactive Investors - Run By Investors For Investors

Sareum announces £700,000 fundraising to support drug development programmes

The company placed 100 mln new ordinary shares of 0.025p each at a price of 0.7p per share
drugs
Sareum is a specialist cancer drug discovery and development company

Sareum Holdings PLC (LON:SAR) has raised £700,000, before expenses, through a share placement to support drug development programmes and supply working capital.

The specialist cancer drug discovery and development company placed 100 million new ordinary shares of 0.025p each at a price of 0.7p per share.

READ: Latest preclinical data for Sareum’s cancer fighting Chk1 inhibitor impresses

Application has been made for the placing shares to be admitted to trading on the London Stock Exchange, which is expected to happen on 22 November.

The company will have a total of 2.7 billion shares in issue after the placing.

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Related Articles

surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
bacteria
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use